Presentation and Assessment | TAVNEOS® (avacopan)

Indication: TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody...

Indication: TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

Read less

Severe Active Disease
Identifying Patients
BVAS Overview
Testing Considerations
ICD-10 Coding

Severe Active Disease

Severe vasculitis is defined by American College of Rheumatology (ACR) guidelines as having life-threatening or organ-threatening manifestations²
Active vasculitis is defined by ACR guidelines as new, persistent or worsening signs and/or symptoms attributed to GPA or MPA and not related to prior damage²

Identifying Patients

GPA and MPA impact the kidneys or other severe organ-threatening manifestations in about 80%-90% of cases, which can be considered severe active disease^1,2,*

Patients in the ADVOCATE trial presented with a spectrum of clinical manifestations.^3,4

General

Myalgia, arthralgia, fever, weight loss^5,6

ADVOCATE: 68.2% general involvement³

You are now leaving the TavneosPro.com website

Adult patients with severe active ANCA-associated vasculitis (GPA or MPA) might present with disease activity in one or more organs1,2

GPA and MPA impact the kidneys or other severe organ-threatening manifestations in about 80%-90% of cases, which can be considered severe active disease1,2,*

Patients in the ADVOCATE trial presented with a spectrum of clinical manifestations.3,4

General

Adult patients with severe active ANCA-associated vasculitis (GPA or MPA) might present with disease activity in one or more organs^1,2

GPA and MPA impact the kidneys or other severe organ-threatening manifestations in about 80%-90% of cases, which can be considered severe active disease^1,2,*

Patients in the ADVOCATE trial presented with a spectrum of clinical manifestations.^3,4